Complete List of Evaluated Biomarkers.

<p>Complete List of Evaluated Biomarkers.</p

Conditional Logistic Regression Analyses with Bonferroni Step-down Adjustment of Serum Biomarker Levels of AIDS-NHL and control subjects.

<p>SD – standard deviation, NS - non-significant;</p>†<p>concentration expressed as ng/ml, all others expressed in pg/ml; Biomarkers in bold represent consensus markers also selected by non-parametric statistics.</p

A-NHL biomarker pathway analysis.

<p>The Ingenuity Pathway Analysis (IPA) software package was utilized to identify pathways and specific interactions associated with the serum biomarkers identified in the current and previous reports. Biomarkers evaluated from the current study (rectangles) included CCL19, CXCL11, MCP-2, MIP-1δ, IFN-α, IL-11, IL-29, IP-10, M-CSF, sIL-1R1, C3, HPN, SAA, SAP, MMP-9, TIMP-1 and OC. Biomarkers evaluated based on previous findings (ovals) included IL-6, sCD30, IL-10, sCD23, sCD44, sCD27, CRP, BCA-1/CXCL13 and IgE. Solid lines indicate direct interactions, dashed lines indicate indirect interactions.</p

Characteristics of Study Population.

<p>HAART – highly active antiretroviral therapy; HBV/HHV-8 status obtained at time of blood draw; CNS – central nervous system; BL – Burkitt's lymphoma; NOS – not otherwise specified.</p

Prediagnostic distributions of serum biomarker levels.

<p>Levels of 67 biomarkers were evaluated in sera obtained from 135 subjects enrolled in the PLCO cancer screening trial who were subsequently diagnosed with pancreatic cancer and 540 matched controls. Circulating levels of biomarkers demonstrating significant differences between cases and healthy controls are presented. Level of significance: * - p<0.03, ** - p<0.01, *** - p<0.001, **** - p<0.0001.</p

Individual Performance of Significantly Altered Serum Biomarkers.

<p>Cut-point – minimum (maximum for prolactin) value (pg/ml) for diagnosis as case at 95% specificity.</p><p>SN – sensitivity at 95% specificity.</p><p>AUC – area under ROC curve.</p

Biomarker levels in relation to time to diagnosis.

<p>Biomarker levels were plotted against the elapsed time interval between blood draw and cancer diagnosis and plots were evaluated by linear regression. Biomarkers demonstrating slopes differing significantly from zero are presented.</p

Reproducibility of measurements of representative biomarkers in duplicate PLCO samples.

<p>Reproducibility of measurements of representative biomarkers in duplicate PLCO samples.</p

Performance of Multimarker Combinations in PLCO Training and Validation Sets.

<p>*Case/Control set described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094928#pone.0094928-Brand1" target="_blank">[8]</a>.</p>#<p>Statistical significance of differences in SN in comparison with CA 19-9 alone, method descrived in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094928#pone.0094928-Hawass1" target="_blank">[18]</a>.</p><p>SN/SP/AUC – sensitivity/specificity/area under ROC curve.</p><p>MTD 1–12 – months to diagnosis 1–12, samples collected <12 months prior to diagnosis.</p><p>MTD 12–35 – months to diagnosis 12–35, samples collected 12 to 35 months prior to diagnosis.</p

Demographic and Clinical Characteristics of PLCO-selected Study Population.

<p>Demographic and Clinical Characteristics of PLCO-selected Study Population.</p